Mr John McQueen
- Affiliate -Clinical Trials Unit (School of Cancer Sciences)
email:
John.Mcqueen@glasgow.ac.uk
Publications
2023
Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)
2021
Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)
2019
Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)
Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)
Gray, V. et al. (2019) Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer. Journal of the National Cancer Institute, 111(8), pp. 828-836. (doi: 10.1093/jnci/djy215) (PMID:30649440) (PMCID:PMC6695319)
2018
Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)
Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)
Articles
Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)
Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)
Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)
Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)
Gray, V. et al. (2019) Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer. Journal of the National Cancer Institute, 111(8), pp. 828-836. (doi: 10.1093/jnci/djy215) (PMID:30649440) (PMCID:PMC6695319)
Robles-Zurita, J. A. et al. (2018) SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. British Journal of Cancer, 119(11), pp. 1332-1338. (doi: 10.1038/s41416-018-0319-z) (PMID:30420616) (PMCID:PMC6265336)
Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)